“Rising Preference for Combination Therapies and Neuromodulation Technique”
- One prominent trend in the global overactive bladder treatment market is the rising preference for combination therapies and minimally invasive neuromodulation techniques
- Patients and healthcare providers are increasingly turning to multi-modal treatment approaches that combine pharmacologic agents with behavioral therapy or device-based interventions for better long-term symptom management
- For instance, combining antimuscarinic drugs with beta-3 adrenergic agonists has shown improved efficacy and reduced side effects, while neuromodulation devices such as sacral nerve stimulation and percutaneous tibial nerve stimulation are gaining traction as alternatives for drug-resistant OAB cases
- This trend is also fueled by advancements in wearable and implantable neuromodulation technologies, which offer more convenient, non-systemic treatment options with fewer adverse effects
- As a result, the market is experiencing a shift toward more personalized, integrated treatment plans that not only enhance patient adherence but also improve overall therapeutic outcome
